Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Oxford Lane Capital Corp (OXLC) Price & Performance

CVS Health CorpTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Oxford Lane Capital Corp — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while Oxford Lane Capital Corp trades at $9.16 (market cap $891.54M). The key difference: CVS Health Corp is far larger — about 152× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.29%). Which is the better fit depends on your goals.

CVSOXLC
Market Cap
$135.48B$891.54M
Sector
HealthFinancials
52-Week High
$106.18$20.80
52-Week Low
$58.75$8.15
Enterprise Value
$202.02B
Dividend Yield
2.51%26.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

Oxford Lane Capital Corp

OXLC trades at $9.19, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. The company reported a net income margin of 100.85% for 2025, but earnings misses and a sharp revenue decline to -$580M in 2026 highlight volatility. Recent news includes dividend declarations and a net asset value update from Oxford Lane Capital on June 15, 2026.

Outlook is cautious due to inconsistent earnings and high yield sustainability concerns. Risks include NAV decay and competitive pressures, while opportunities lie in dividend income. Analyst consensus is split, with 50% buy ratings but significant sell coverage citing fund performance issues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC